Latest Articles:
Stay in the Know
StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for its HPC, Cord Blood product REGENECYTE™, a vital cord blood stem cell therapy for transplantation in patients with blood and immune system disorders.
StemCyte announced today that its Hematopoietic Progenitor Cell Cord Blood therapy (HPC Cord Blood) has officially obtained the Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for the treatment of Long COVID-19 syndrome.
StemCyte's CEO explains why the company is ready for an IPO. In addition to operating a multi-national hybrid bank, StemCyte is also manufacturing immunotherapies from cord blood and is one of the industry's leaders in running clinical trials with cord blood.
Parent's Guide to Cord Blood Interview with StemCyte CEO Tong-Young Lee PhD
May 2024
"I didn't expect that the umbilical cord blood saved for the child would actually save the child's life 19 years later!" said the father of Xiaoan, an aplastic anemia patient, excitedly. To learn more about cord blood banking.
Cured by his own cord blood 19 years later
Oct. 2023
In this story, a child that underwent a prolonged cardiac arrest was resuscitated but remained in a vegetative state because of the pause in blood flow to his brain. After an infusion of his own cord blood, he experienced a remarkable recovery over the next three years that has been published in the medical literature.
Cord Blood Rescue After Cardiac Arrest
Aug. 2023
As international demand for starting substances for use in cell therapy emerges, California-based regenerative therapeutics company StemCyte announced it has signed a cooperation agreement with a leading US cell therapy company that is developing allogeneic genetically modified CAR-NK cells using umbilical cord blood. StemCyte has agreed to supply the necessary cellular raw materials for allogeneic cell therapy product development worldwide.
StemCyte signs a cooperation agreement with US immune cell therapy company
June 2023
Peleg had a typical case of autism with regression. His parents decided to try cell therapy. Before and after videos document his rapid improvement in language skills.
Peleg's Story of Cell Therapy for Autism
June 2023
Salvador is a 5-year-old boy from Portugal diagnosed with Autism Spectrum Disorder who received cord blood therapy in the US through the Expanded Access program at Duke.
Salvador’s Story: Expanded Access for Autism
May 2023
StemCyte announced it has officially begun recruiting patients under a US Food and Drug Administration (FDA) approved Phase IIa human clinical trial in the United States. This is the world's first Phase II trial using umbilical cord blood cells to treat Post-COVID syndrome.
